Close Menu

NEW YORK – Cancer early detection firm Singlera is pushing forward to commercialize a DNA-methylation-based assay called PanSeer with an immediate focus on colorectal cancer, but potential to expand that to a more pan-cancer setting in the future.

The company, which was founded in 2014 and has offices in California and Shanghai, reached a milestone this month with the publication of promising data from a study of the assay's performance in a longitudinal cohort of cancer-free individuals — the intended use population for this type of screening test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.